Compare Medpace Holdings Inc (MEDP) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs VanEck Vietnam ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while VanEck Vietnam ETF trades at $16.72 (market cap $469.76M). The key difference: Medpace Holdings Inc is far larger — about 35.8× VanEck Vietnam ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and VanEck Vietnam ETF for 51 Days on average.
| MEDP | VNM | |
|---|---|---|
Market Cap | $16.82B | $469.76M |
Volume | 223,093 | 375,157 |
Sector | Health | Sector/Thematic |
52-Week High | $630.19 | $19.80 |
52-Week Low | $393.42 | $16.34 |
Typical Hold Time | 14 Days | 51 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
VNM trades at $16.72, down 0.89% today, with a bearish technical signal from moving averages but bullish momentum from oscillators. The stock faces sector concentration risks in real estate and financials while benefiting from Vietnam's potential US trade deal progress. Key support and resistance cluster around $17, with RSI levels indicating potential oversold conditions.
The outlook remains cautious due to sector headwinds and interest rate sensitivity, though fair valuation and macroeconomic growth prospects offer long-term potential. Near-term performance depends on trade developments and sector stability, with institutional sentiment mixed on timing and risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
